Compare NUVL & STWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | STWD |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 7.4B |
| IPO Year | 2021 | 2009 |
| Metric | NUVL | STWD |
|---|---|---|
| Price | $101.45 | $17.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 4 |
| Target Price | ★ $135.00 | $20.63 |
| AVG Volume (30 Days) | 485.1K | ★ 3.2M |
| Earning Date | 10-30-2025 | 11-10-2025 |
| Dividend Yield | N/A | ★ 10.32% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.04 |
| Revenue | N/A | ★ $490,651,000.00 |
| Revenue This Year | N/A | $366.38 |
| Revenue Next Year | N/A | $12.15 |
| P/E Ratio | ★ N/A | $17.87 |
| Revenue Growth | N/A | ★ 12.42 |
| 52 Week Low | $55.54 | $16.59 |
| 52 Week High | $112.88 | $21.05 |
| Indicator | NUVL | STWD |
|---|---|---|
| Relative Strength Index (RSI) | 45.84 | 40.23 |
| Support Level | $99.38 | $18.44 |
| Resistance Level | $106.65 | $18.62 |
| Average True Range (ATR) | 2.78 | 0.20 |
| MACD | -0.75 | -0.02 |
| Stochastic Oscillator | 24.04 | 0.00 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Starwood Property Trust Inc is an American real estate investment trust principally engaged in originating, acquiring, and managing commercial mortgage loans and commercial mortgage-backed securities in the U.S. and Europe. The company organizes its activities into Commercial and Residential Lending Segment, Infrastructure Lending Segment, Property Segment, and Investing & Servicing Segment. The company generates the majority of its revenue from the Commercial and Residential Lending Segment, which is engaged in originating, acquiring, financing, and managing commercial first mortgages, and non-agency residential mortgages.